Physician profile
Leon Rawner
NPI 1700105616
$4,102.40
in general payments reported to CMS, 2019-2025
24 companies · $506 in 2025
The $506 reported for 2025 was more than what 84% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $380 · 2021: $645 · 2022: $529 · 2023: $657 · 2024: $720 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $657.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $562.42 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $490.88 | 2019-2022 | |
| Novo Nordisk INC | $391.92 | 2021-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $362.54 | 2019-2025 | |
| Amgen INC. | $303.25 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $219.01 | 2019-2022 | |
| Lilly USA, LLC | $178.22 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $171.83 | 2019-2025 | Airsupra |
| Horizon Therapeutics Plc | $108.51 | 2022-2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $107.54 | 2021-2024 | Xarelto |
| Abbott Laboratories | $96.07 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.26 | 2024 | Xifaxan |
| Shield Therapeutics INC | $75.95 | 2023 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.30 | 2019-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58.98 | 2022-2023 | |
| Genentech USA, INC. | $37.68 | 2020-2021 | |
| Alk-Abello, INC | $35.83 | 2019 | |
| Smith+Nephew, INC. | $27.34 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.19 | 2024 | Recorlev |
| Abbvie INC. | $16.67 | 2022 | |
| Linus Health, INC. | $16.15 | 2024 | Core Cognitive Evaluation |
| Esperion Therapeutics, INC. | $15.20 | 2024 | Nexletol |
| Allergan, INC. | $14.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Rawner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.